8-K: Day One Completes Mersana Acquisition, Expands Oncology Pipeline

Day One Biopharmaceuticals successfully acquired Mersana Therapeutics, adding clinical-stage antibody drug conjugate Emi-Le and expanding its oncology pipeline.

Summary

• Day One Biopharmaceuticals, Inc. completed the acquisition of Mersana Therapeutics, Inc. on January 6, 2026.
• The acquisition involved a tender offer to purchase all outstanding shares of Mersana common stock for $25.00 per share in cash, plus one non-tradable contingent value right (CVR) per share, representing the right to receive certain contingent payments of up to an aggregate of $30.25 per CVR in cash.
• The total potential consideration per share is up to $55.25.
• A total of 3,029,135 Mersana shares, representing approximately 60.57% of the issued and outstanding Mersana common stock, were validly tendered and not validly withdrawn.
• The aggregate cash paid by Day One and Merger Sub in the Offer and Merger was approximately $128.8 million, funded from available cash on hand.
• Mersana became a direct wholly-owned subsidiary of Day One, and its common stock ceased trading on the Nasdaq stock exchange prior to market open on January 6, 2026.
• The acquisition expands Day One's pipeline with emiltatug ledadotin (Emi-Le), a clinical-stage antibody drug conjugate (ADC) targeting B7-H4 for adenoid cystic carcinoma (ACC).
• Day One reported strong Q3 2025 performance for OJEMDA, with $38.5 million in net product revenue, representing 15% sequential growth.
• New patient starts for OJEMDA grew by 19% and total prescriptions grew by 18% sequentially in Q3 2025.
• Full-year 2025 guidance for OJEMDA net product revenue was raised to $145-$150 million.

Sentiment

Score: 8

Explanation: The acquisition of Mersana Therapeutics significantly expands Day One's pipeline with a promising clinical-stage asset (Emi-Le) targeting a high-unmet-need rare cancer, aligning with strategic growth. This is further bolstered by strong commercial performance and raised guidance for its existing key product, OJEMDA. While CVRs introduce some uncertainty, the overall strategic and operational updates are highly positive for future growth.

Positives

• Strategic acquisition significantly expands the clinical pipeline with Emi-Le, a novel ADC targeting B7-H4 for the rare cancer adenoid cystic carcinoma (ACC).
• Emi-Le has promising early clinical data and addresses a clear unmet medical need in ACC, a condition with no currently approved therapies.
• Strong commercial execution of OJEMDA, with Q3 2025 net product revenue reaching $38.5 million, demonstrating 15% sequential growth.
• Significant sequential growth in OJEMDA new patient starts (19%) and total prescriptions (18%) in Q3 2025, indicating robust market uptake.
• Raised full-year 2025 guidance for OJEMDA net product revenue to $145-$150 million, reflecting strong market momentum and confidence.
• High persistency and increasing second-line adoption for OJEMDA, with a median duration of treatment of 20 months for EAP patients.
• DAY301, a PTK7-targeted ADC, shows encouraging preclinical activity and potential as a next-generation therapeutic with an improved therapeutic index.

Negatives

• Contingent Value Rights (CVRs) are non-tradable, limiting liquidity for former Mersana shareholders.
• There is no assurance that any CVR milestones will be achieved or that any Milestone Payments will be made, introducing uncertainty regarding the full potential consideration.
• The acquisition involved a significant cash outlay of approximately $128.8 million.
• Risks associated with integrating acquired businesses, which may be difficult, time-consuming, or costly, and may not yield expected benefits.

Risks

• Outcome of legal proceedings that may be instituted against Day One and/or others relating to the transactions may result in significant costs of defense, indemnification, and liability.
• Disruption from the transactions, making it more difficult to conduct business as usual or maintain relationships with customers, employees, or suppliers.
• Risk that Day One will not be able to retain Mersana employees following the closing of the transaction.
• Risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, or that integration may be more difficult, time-consuming, or costly than expected.
• Risk that the expected benefits of the transaction will not occur.
• Risks associated with developing product candidates, including unforeseen delays that may impact the timing of clinical trials and data reporting.
• Uncertainty of the expected financial performance of Target and its product candidates.
• Possibility that the Milestone Payments related to the CVRs will never be achieved and that no Milestone Payment may be made.
• Possibility that if Target does not achieve the perceived benefits of the proposed transaction as rapidly or to the extent anticipated by financial analysts or investors, the market price of Day One's shares could decline.

Future Outlook

Day One plans to continue driving revenue growth from OJEMDA globally, expand its indication in front-line pediatric low-grade glioma (pLGG) with the FIREFLY-2 trial, generate clinical proof-of-concept data in the DAY301 program, and advance Emi-Le toward registrational development in adenoid cystic carcinoma (ACC). The company aims to maintain a strong financial foundation through thoughtful capital allocation and expand its impact on patient communities while delivering sustainable business growth.

Management Comments

• "This acquisition of Mersana is a strategic fit with Day One's mission and ambitions, allowing us to continue to expand into adult oncology while maintaining a focus on rare cancers."
• "With promising early clinical data, Emi-Le represents a potentially transformative advancement in the treatment of ACC, and we will leverage our distinct capabilities to rapidly develop the asset and pursue registration to reach patient communities who have no approved therapies today."
• "Building on the strong momentum of OJEMDA in the market and our continually progressing pipeline, this acquisition strengthens our overall position to expand our impact on patient communities while delivering sustainable business growth."

Industry Context

The acquisition signifies Day One's strategic expansion into adult oncology, particularly rare cancers like adenoid cystic carcinoma (ACC), complementing its existing focus on pediatric oncology (OJEMDA for pLGG). The addition of Emi-Le, an antibody drug conjugate (ADC), aligns with a growing trend in targeted cancer therapies, leveraging a well-characterized target (B7-H4) in an area of high unmet medical need. The company also highlights its second novel ADC, DAY301, targeting PTK7, indicating a broader strategic focus on the ADC space.

Comparison to Industry Standards

• Emi-Le is presented as a "Potential First-in-Class B7-H4-targeted ADC opportunity in ACC," addressing a rare cancer with no approved therapeutic options, positioning it favorably against the current standard of care (or lack thereof).
• DAY301 is described as a "next-generation PTK7 ADC with improved therapeutic index" compared to prior programs like cofetuzumab pelidotin, which demonstrated activity but was limited by toxicity, suggesting an attempt to overcome known industry challenges with similar targets.
• OJEMDA's performance, with 15% sequential revenue growth and high persistency, indicates strong market acceptance in the pediatric low-grade glioma segment, potentially outperforming typical new drug launches in niche markets.

Legal Proceedings

• Potential legal proceedings may be instituted against Day One and/or others relating to the transactions, which could result in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Former Mersana shareholders receive upfront cash and CVRs, which offer potential future payments but are non-tradable and subject to milestone achievement. Day One shareholders benefit from pipeline expansion and potential future revenue streams.
• Employees: Risk of disruption and difficulty in retaining Mersana employees following the acquisition.
• Customers/Patients: Potential for new therapeutic options, particularly for patients with adenoid cystic carcinoma (ACC) who currently have no approved therapies.

Next Steps

• Achieve CVR milestones for Emi-Le, including FDA breakthrough therapy designation, first patient dosing in a registrational trial for ACC-1, FDA regulatory approval for ACC-1, and various net sales milestones.
• Continue enrollment for the FIREFLY-2 pivotal Phase 3 trial for tovorafenib in front-line pediatric low-grade glioma (pLGG).
• Outline development timelines and data presentation for the DAY301 program in 2026.
• Receive EMA regulatory decision for OJEMDA in 2026.
• File financial statements of the acquired business and pro forma financial information by amendment within 71 calendar days.

Key Dates

Recommendation

The acquisition of Mersana Therapeutics is a highly strategic move, significantly expanding Day One's oncology pipeline with Emi-Le, a clinical-stage ADC targeting a rare cancer with substantial unmet need. This complements the strong commercial momentum of OJEMDA, which continues to demonstrate robust revenue growth and market penetration, leading to raised financial guidance. The company's focus on developing firstor best-in-class medicines for both pediatric and adult cancers, coupled with a solid financial position, positions it for sustainable long-term growth. While CVRs introduce some contingent risk, the overall expansion of the asset portfolio and proven commercial execution warrant a strong buy recommendation for investors seeking growth in the biopharmaceutical sector.

Keywords

Biopharmaceuticals, Acquisition, Merger, Oncology, ADC, Antibody Drug Conjugate, Emi-Le, Emiltatug Ledadotin, B7-H4, Adenoid Cystic Carcinoma, ACC, Mersana Therapeutics, Day One Biopharmaceuticals, DAWN, CVR, Contingent Value Right, OJEMDA, Tovorafenib, Pediatric Low-Grade Glioma, pLGG, Pipeline Expansion, Clinical Development, Rare Cancer, Financial Results, Q3 2025, Guidance